Danaher DHR · NYSE
$229.04 -1.06% (-$2.46)
Summary
50 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 16 USD is left as net profit.
- It has raised its dividend 9 years in a row and pays out only 27% of profit.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue fell by 2.7% a year over the last 3 years.
- It earns only 5.0 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 40.6 USD for 1 USD of yearly profit. Over the last five years it was 36.4 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 2.0% a year over 5 years. Over the last 3 years it fell by 2.7% a year. For the next fiscal year analysts expect revenue to grow by 7.3%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 41 USD
- Research and development 6.4 USD
- Sales and administration 32 USD
- Taxes and other 4.5 USD
- Net profit 16 USD
Net profit, industry median (Medical - Diagnostics & Research) 8.8 USD
Out of every 100 USD of revenue, 16 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 4.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.66%
- Paid out of profit
- 27%
- Raised in a row
- 9 years
You receive $1.52 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 30
- Hold 12
- Sell 1
Today's price within the analysts' price targets
The average target of $230.31 is 0.6% above today's price. 70% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Revenue from Contract with Customer, Measurement, Recurring 82%
- Revenue from Contract with Customer, Measurement, Nonrecurring 18%
By region
- Other developed markets 82%
- CHINA 18%
Revenue from Contract with Customer, Measurement, Recurring brings in 82% of revenue.
Segments in detail